Big pharma companies are partnering with artificial intelligence (AI) firms with hopes to improve key aspects of the healthcare industry such as drug discovery and ultimately save time and reduce R&D costs. However, it is important to train and monitor the performance of these systems to avoid errors such as security breaches, says data and analytics company GlobalData.
American biotech firm Celgene partnered with GNS Healthcare to use its Reverse Engineering and Forward Simulation causal machine learning and simulation platform. GSK entered into a $43m drug discovery collaboration with UK-based AI-driven startup Exscientia. Pfizer collaborated with IBM Watson for immuno-oncology drug discovery research.
Exscientia is at the forefront of Artificial Intelligence-driven drug discovery and design. As at 8th January 2019, Frontier IP Group Plc (LON:FIPP) have a 3.3% holding in Exscientia. Frontier IP Group, through its subsidiaries, engages in assisting universities, research institutions, and companies in the commercialization and exploitation of their intellectual property (IP) in the United Kingdom.